… were demonstrated in a phase I study, 13 and a phase II study showed 18% remission
and … These studies supported the initiation of a phase III program. Our current study (CLAVELA, …

Background This study compared irinotecan plus cisplatin (IP) with etoposide plus cisplatin (EP)
in small-cell lung cancer patients with extensive disease. Patients and methods Patients …

… This large randomized placebo-controlled phase III trial … In phase I and II trials, ridaforolimus
demonstrated clinical … In a nonrandomized phase II trial in patients with advanced sarcomas, …

… This study compared overall and disease-free survival in patients receiving BCG plus … after
resection of stage III (n = 1,160) or stage IV (n = 496) melanoma were randomly assigned to …

… This trial assessed the benefit of mFOLFIRINOX in the adjuvant setting. Methods: PRODIGE
24/CCTG PA.6 is a phase III multicenter, randomized clinical trial. Pts aged 18-79 years with …

PURPOSE We previously reported that enzalutamide improved overall survival when added
to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its …

… phase III study in patients with GBMs and unmethylated MGMT promoter and the first
prospective phase III study … The benefit of this treatment was demonstrated in a phase III study, …

Purpose We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial
growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined …

Methods BetweenJune 2007 and March 2017, 1080 patients with clinical stage IA who
metpreoperative eligibility criteria were registered for the trial. Intra-operative eligibility required …

… The primary end point of the study was change in PSA from baseline to 12 weeks. The …
from the phase II trial by Danila et al 19 and the much larger, randomized phase III trial in the …